Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like CTI BioPharma Reports First Quarter 2017 Financial Results May 3, 2017 J&J Exec Reveals How You Can Stand Out Among 3,000 Job Seekers November 8, 2017 The Stunning Golden Parachutes of Juno's $9B Celgene Deal February 4, 2018
